KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranibJohn Smith, Juliane M. Jürgensmeier, David M. Wilson et al.|European Journal of Cancer|2013Cited by 16
Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib.J.M. Jürgensmeier, Jeff Smith, P. M. Hoff et al.|Journal of Clinical Oncology|2011Cited by 3
Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models.Denis Alférez, Robert W. Wilkinson, P. Hedge et al.|Molecular Cancer Therapeutics|2011Cited by 0